Ipca Laboratories (IPCALAB) | Stock Overview & Key Data
Ipca Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹1,418.60
High: ₹1,463.50
on August 4, 2025
52 Week Range
Low: ₹1,168.20
High: ₹1,755.90
on April 7, 2025
on January 7, 2025
All-Time High: ₹1,755.90 on January 6, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR367.9B
EPS
29.04
P/E Ratio (TTM)
49.94
Forward P/E
30.31
P/B Ratio
5.30
PEG Ratio
30.31
Div. Yield
0.29%
ROE
9.74%
Beta
0.216
Debt to Equity
16.25
Financial Highlights
Profitability
Gross Margin
68.47%
Operating Margin
13.24%
Profit Margin
8.25%
Returns and Earnings
Return on Assets (TTM)
7.09%
Return on Equity (TTM)
9.74%
EBITDA
INR18.2B
Net Income (TTM)
INR7.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR352.43
Quarterly Revenue Growth (YoY)
10.50%
Quarterly Earnings Growth (YoY)
13.80%
Dividend Information
Last 12-Month Dividend
₹4.00
Current Dividend Yield
0.29%
3-Year Average Dividend Yield
0.23%
3-Year Average Annual Dividend
₹3.33
3-Year Total Dividends
₹10.00
Ex-Dividend Date
November 27, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ipca Laboratories IPCALAB | 367.92B Large-cap | -3.90% | 5.71% | 5.13% | 2.42% | -14.34% | 11.53% | 43.24% | 48.23% |
| Sun Pharmaceutical SUNPHARMA | 3.91T Large-cap | -4.08% | -2.25% | -10.68% | -6.46% | -13.77% | -5.89% | 77.92% | 209.86% |
| Divi's Laboratories DIVISLAB | 1.69T Large-cap | -3.85% | -7.22% | 4.64% | 13.22% | 4.75% | 27.45% | 62.61% | 128.43% |
| Torrent TORNTPHARM | 1.24T Large-cap | 2.06% | 7.65% | 13.78% | 14.76% | 7.60% | 13.94% | 136.30% | 25.06% |
| Cipla CIPLA | 1.21T Large-cap | -1.94% | -0.85% | -1.49% | 4.40% | 1.58% | 4.40% | 45.31% | 106.24% |
| Mankind Pharma MANKIND | 1.06T Large-cap | -1.43% | 12.21% | 7.81% | 3.56% | -10.92% | 28.31% | 84.04% | 84.04% |
Ownership & Short Interest
Insider Ownership
45.05%
Institutional Ownership
41.37%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
375K
Average 90-Day Volume
262K
Ipca Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ipca Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IPCALAB's 52-week high and low?
- In the last 52 weeks, Ipca Laboratories reached a high of ₹1,755.90 (on January 7, 2025) and a low of ₹1,168.20 (on April 7, 2025).
- What is the market cap and P/E ratio for IPCALAB?
- Curious about Ipca Laboratories's size and valuation? Its market capitalization stands at 367.92B. When it comes to valuation, the P/E ratio (trailing twelve months) is 49.94, and the forward P/E (looking ahead) is 30.31.
- Does IPCALAB pay dividends? If so, what's the yield?
- Yes, Ipca Laboratories is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.29%, and the company has paid an average of ₹3.33 per share annually over the past 3 years.
- Who are Ipca Laboratories's main competitors or similar companies to consider before investing?
When looking at Ipca Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.91T Healthcare Drug Manufacturers - Specialty & Generic -5.89% 77.92% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 27.45% 62.61% Torrent
TORNTPHARM1.24T Healthcare Drug Manufacturers - Specialty & Generic 13.94% 136.30% Cipla
CIPLA1.21T Healthcare Drug Manufacturers - Specialty & Generic 4.40% 45.31% Mankind Pharma
MANKIND1.06T Healthcare Drug Manufacturers - Specialty & Generic 28.31% 84.04% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ipca Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Ipca Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.74%, the Debt to Equity ratio from the most recent quarter is 16.25, and its Gross Profit Margin stands at 68.47%.
- What is the recent revenue and earnings growth for IPCALAB?
- Looking at Ipca Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR89B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.50%, and quarterly earnings saw a YoY growth of 13.80%.
- How much of IPCALAB stock is held by insiders and institutions?
- Wondering who owns Ipca Laboratories stock? Company insiders (like executives and directors) hold about 45.05% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 41.37%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.